UniXell Biotechnology Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$7.19M
- Investors
-
21
UniXell Biotechnology General Information
Description
Developer of cellular therapy designed for human pluripotent stem cells. The company offers unmet medical needs, including neurodegenerative diseases and rare diseases, and it has developed multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology and high-precision gene editing, thereby providing effective treatment solutions for patients afflicted with neurodegenerative disorders, rare diseases, and tumors.
Contact Information
Website
unixell.comCorporate Office
- 5th Floor, Block D, Free Trade Zone
- Number 215 Huashen Road, Pudong New Area
- Shanghai, 200131
- China
Corporate Office
- 5th Floor, Block D, Free Trade Zone
- Number 215 Huashen Road, Pudong New Area
- Shanghai, 200131
- China
UniXell Biotechnology Timeline
UniXell Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A1) | 11-Feb-2026 | $7.19M | Completed | Generating Revenue | ||
| 5. Early Stage VC (Series A1) | 06-Nov-2025 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A1) | 12-Jul-2024 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 31-Mar-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 29-Mar-2022 | $31.5M | $31.5M | Completed | Generating Revenue | |
| 1. Seed Round | 25-Aug-2021 | Completed | Startup |
UniXell Biotechnology Patents
UniXell Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026222936-A1 | Method for differentiation of medial ganglionic eminence neural progenitor cells | Pending | 23-Apr-2025 | ||
| WO-2025252180-A1 | In-vitro preparation method for midbrain dopaminergic progenitor cell population | Pending | 05-Jun-2024 | ||
| WO-2025162486-A1 | An additive composition and a method for promoting differentiation into a10 precursors and/or a10 neurons | Pending | 31-Jan-2024 | ||
| US-20240207324-A1 | Method for quality control and enrichment of human dopaminergic neural precursor cells | Pending | 21-Apr-2021 | ||
| WO-2022222974-A1 | Method for quality control and enrichment of human dopaminergic neural precursor cells | Inactive | 21-Apr-2021 | A61K35/30 |
UniXell Biotechnology Signals
UniXell Biotechnology Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Panlin Capital | Venture Capital | Minority | ||
| Fosun Health Capital | Corporate Venture Capital | Minority | ||
| Shanghai Guotou Pioneer Private Equity Fund Management | Fund of Funds | Minority | ||
| Shanghai Pudong Venture Capital | Venture Capital | Minority | ||
| Shanghai State Owned Capital Investment | Government | Minority |
UniXell Biotechnology FAQs
-
When was UniXell Biotechnology founded?
UniXell Biotechnology was founded in 2021.
-
Where is UniXell Biotechnology headquartered?
UniXell Biotechnology is headquartered in Shanghai, China.
-
What is the size of UniXell Biotechnology?
UniXell Biotechnology has 40 total employees.
-
What industry is UniXell Biotechnology in?
UniXell Biotechnology’s primary industry is Biotechnology.
-
Is UniXell Biotechnology a private or public company?
UniXell Biotechnology is a Private company.
-
What is UniXell Biotechnology’s current revenue?
The current revenue for UniXell Biotechnology is .
-
How much funding has UniXell Biotechnology raised over time?
UniXell Biotechnology has raised $66.6M.
-
Who are UniXell Biotechnology’s investors?
Panlin Capital, Fosun Health Capital, Shanghai Guotou Pioneer Private Equity Fund Management, Shanghai Pudong Venture Capital, and Shanghai State Owned Capital Investment are 5 of 21 investors who have invested in UniXell Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process